Stockscreener 앱 받기
15.35
11.56%
1.59
시간 외 거래:
15.36
0.010
+0.07%
Syndax Pharmaceuticals Inc 주식(SNDX)의 최신 뉴스
Syndax Pharmaceuticals (SNDX) Is Up 13.6% After FDA Approval Expands Revuforj Use in AML - Yahoo Finance
Syndax Pharmaceuticals: Q3 Earnings Call Highlights - TipRanks
Syndax Pharmaceuticals Inc (SNDX) Q3 2025 Earnings Call Highligh - GuruFocus
Syndax Pharmaceuticals Inc (SNDX) Q3 2025 Earnings Call Highlights: Strong Revenue Growth ... - Yahoo Finance
Syndax Pharmaceuticals (NASDAQ:SNDX) Announces Earnings Results - MarketBeat
Syndax Pharmaceuticals stock maintains Buy rating at Stifel despite sales disconnect - Investing.com Canada
SNDX: UBS Raises Price Target to $38, Maintains Buy Rating | SND - GuruFocus
Barclays Raises Price Target for Syndax Pharmaceuticals (SNDX) t - GuruFocus
Goldman Sachs raises Syndax Pharmaceuticals stock price target on growth outlook - Investing.com Canada
Is Syndax Pharmaceuticals Inc. (1T3) stock considered safe havenJuly 2025 Review & AI Enhanced Trade Execution Alerts - newser.com
Syndax: Q3 Earnings Snapshot - CT Insider
Decoding Syndax Pharmaceuticals Inc (SNDX): A Strategic SWOT Insight - GuruFocus
Syndax Pharmaceuticals Reports Strong Q3 2025 Growth - TipRanks
Syndax Pharmaceuticals (SNDX) Q3 2025 Earnings: Revenue Jumps 21% - GuruFocus
Syndax targets $10B market as Revuforj gains NPM1 approval and Q3 revenue rises 21% - MSN
Will Syndax Pharmaceuticals Inc. stock maintain momentum in 2025July 2025 Setups & Safe Swing Trade Setup Alerts - newser.com
Syndax Pharmaceuticals Q3 2025 Earnings Call Transcript - MarketBeat
Transcript : Syndax Pharmaceuticals, Inc., Q3 2025 Earnings Call, Nov 03, 2025 - MarketScreener
Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Lags Revenue Estimates - sharewise.com
Is Syndax Pharmaceuticals Inc. stock reversal real or fakeGap Down & Weekly High Potential Alerts - newser.com
Syndax Pharmaceuticals Q3 Earnings: EPS of -$0.70 Beats Estimate, Revenue of $45.9M Misses Estimate - GuruFocus
Syndax Pharmaceuticals Grows Revenue As Wall Street Stays Bullish - Finimize
Syndax Pharmaceuticals falls as Q3 revenue misses estimates - Investing.com India
Earnings Flash (SNDX) Syndax Pharmaceuticals, Inc. Reports Q3 Revenue $45.9M, vs. FactSet Est of $48.0M - MarketScreener
Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update - The Manila Times
[10-Q] Syndax Pharmaceuticals Inc Quarterly Earnings Report | SNDX SEC FilingForm 10-Q - Stock Titan
[8-K] Syndax Pharmaceuticals Inc Reports Material Event | SNDX SEC FilingForm 8-K - Stock Titan
SNDX: Syndax Pharmaceuticals to Showcase Promising Data at ASH 2 - GuruFocus
Is Syndax Pharmaceuticals Inc. stock poised for growth2025 Technical Overview & Low Volatility Stock Recommendations - newser.com
Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025 - The Manila Times
Syndax Announces Compelling Revuforj® (revumenib) and - GlobeNewswire
Syndax (NASDAQ: SNDX) to present Revuforj and Niktimvo data in 23 ASH 2025 abstracts - Stock Titan
How Syndax Pharmaceuticals Inc. stock performs in rate cut cycles2025 Risk Factors & Safe Swing Trade Setup Alerts - newser.com
Using Ichimoku Cloud for Syndax Pharmaceuticals Inc. technicals2025 Big Picture & Entry and Exit Point Strategies - newser.com
Leading vs lagging indicators on Syndax Pharmaceuticals Inc. performanceJuly 2025 Short Interest & Entry Point Confirmation Alerts - newser.com
Is Syndax Pharmaceuticals Inc. (1T3) stock undervalued by metricsMarket Activity Recap & Weekly Momentum Picks - newser.com
AlphaQuest LLC Sells 18,370 Shares of Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Applying Wyckoff theory to Syndax Pharmaceuticals Inc. stockBreakout Watch & Verified Technical Trade Signals - newser.com
Detecting support and resistance levels for Syndax Pharmaceuticals Inc.Jobs Report & Verified Swing Trading Watchlist - newser.com
Is it too late to sell Syndax Pharmaceuticals Inc.Weekly Trade Summary & Growth-Oriented Investment Plans - newser.com
How Syndax Pharmaceuticals Inc. stock performs in stagflationJuly 2025 Chart Watch & Verified Momentum Watchlists - newser.com
Syndax Pharmaceuticals Q3 2025 Earnings Preview - MSN
Is Syndax Pharmaceuticals Inc. showing signs of accumulationMarket Volume Summary & AI Driven Stock Movement Reports - newser.com
Syndax Pharmaceuticals (SNDX) Q3 Earnings Preview: Key Expectati - GuruFocus
Kura Oncology's Ziftomenib Poised For Differentiation (NASDAQ:KURA) - Seeking Alpha
How risky is Syndax Pharmaceuticals Inc. stock nowJuly 2025 Recap & Free Technical Pattern Based Buy Signals - newser.com
Y Intercept Hong Kong Ltd Makes New Investment in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
B. Riley Issues Optimistic Estimate for SNDX Earnings - MarketBeat
Syndax Pharmaceuticals Inc (SNDX) Q3 2025 Earnings Report Preview: What To Expect - Yahoo Finance
Syndax Pharmaceuticals Inc (SNDX) Q3 2025 Earnings Report Previe - GuruFocus
1.45%
0.86%
자본화:
|
볼륨(24시간):